Advertisement
Organisation › Details
Evotec (Group)
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *
Start | 2001-10-02 existent | |
Industry | drug discovery technology | |
Industry 2 | drug discovery services | |
Region | Hamburg | |
Country | Germany | |
Street | 7 Essener Bogen Manfred Eigen Campus | |
City | 22419 Hamburg | |
Tel | +49-40-56081-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | G: 5,001 to 10,000 (2023-12-31) |
Currency | EUR | |
Annual sales | 781,426,000 (revenues, consolidated (2023) 2023-12-31) | |
Profit | -83,913,000 (2023-12-31) | |
Cash | 510,909,000 (2023-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-04-29 |
Advertisement
More documents for Evotec (Group)
- [1] Evotec SE. (7/6/22). "Press Release: Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance". Germany & France....
- [2] Biognosys AG. (9/14/21). "Press Release: Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-Generation Proteomics". Schlieren....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
» top